<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/102F2A51-71E4-4ECA-A245-9B9C4858D7E4"><gtr:id>102F2A51-71E4-4ECA-A245-9B9C4858D7E4</gtr:id><gtr:name>MRC Harwell</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:department>Kennedy Institute</gtr:department><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/102F2A51-71E4-4ECA-A245-9B9C4858D7E4"><gtr:id>102F2A51-71E4-4ECA-A245-9B9C4858D7E4</gtr:id><gtr:name>MRC Harwell</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/E0A0B6CE-6C5B-460E-958F-1AAFC9448905"><gtr:id>E0A0B6CE-6C5B-460E-958F-1AAFC9448905</gtr:id><gtr:firstName>Fionula</gtr:firstName><gtr:otherNames>Mary</gtr:otherNames><gtr:surname>Brennan</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/0739CA32-9E20-4C8D-BBB9-86618DFBB3E9"><gtr:id>0739CA32-9E20-4C8D-BBB9-86618DFBB3E9</gtr:id><gtr:firstName>Nicole</gtr:firstName><gtr:surname>Horwood</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0900160"><gtr:id>063BA228-34D1-465D-84BA-D59712254C53</gtr:id><gtr:title>Natural Killer Cells: Role in the pathogenesis of rheumatoid arthritis major contributors or essential homeostatic modu</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0900160</gtr:grantReference><gtr:abstractText>Rheumatoid arthritis is a global health problem caused by chronic inflammation in affected joints. Our group identified that a protein called Tumour Necrosis Factor (TNF) was central to the destructive processes in the disease rheumatoid arthritis. These observations led to the development of new drugs, which block the action of TNF, and were demonstrated to be extremely effective in RA patients. These anti-TNF drugs have now been used successfully in over 1,000,000 patients worldwide. Whilst this therapy is effective, it is not a cure and we are continuing to investigate other targets in this disease which will lead to treatments which are even more effective and safer for the patients. The chronic inflammation in RA has been demonstrated to be due to persistent production of TNF in the diseased joint which is dependent on a subset of T cells. Recently we have described how surrogates for these rheumatoid arthritis T cells can be generated using T lymphocytes from normal peripheral blood stimulated in culture with a cocktail of cytokines that are present within the rheumatic joint. We also found that within the T cell population there is a large number of natural killer cells that demonstrate pathogenic properties towards cells of bone; a tissue destroyed in RA joints. In this proposal we wish to translate our current knowledge and understanding of NK cells into an in vivo model of rheumatoid arthritis. We anticipate that the study will lead to a better understanding of the mechanisms involved in driving chronic inflammation in rheumatoid arthritis and identify new novel targets for therapeutic intervention.</gtr:abstractText><gtr:technicalSummary>Rheumatoid arthritis (RA) is a chronic inflammatory disease that affects more than 1% of the world population. Although anti-TNF drugs are the most successful therapy to date, only 70% of patients benefit from this treatment. Therefore, it is imperative we have better understanding of the mechanisms underlying the establishment of chronic inflammation. Whilst the role of cytokines (particularly TNF) in contributing to the pathogenesis of RA has been well documented, the role of T lymphocytes has remained unclear, and the involvement of NK cells not fully understood. NK cells are interesting candidates for therapy since despite their low frequency they are the ?main producers? of interferon gamma at inflammatory sites. Our group has recently shown that surrogates for RA synovial T cells can be generated ex vivo using T lymphocytes from normal peripheral blood stimulated in culture with a cocktail of cytokines (TNF, IL-6 and IL-2). Within this lymphocyte population there is a significant expansion of activated NK cells which, when sorted, are potent effectors of contact-mediated activation of monocytes, macrophages and osteoclasts. In this proposal we wish to translate our current (and limited) knowledge and understanding of cytokine-activated NK cells into the RA-SCID in vivo model of rheumatoid arthritis. We believe this model will allow us to dissect the potential of NK cells to contribute to inflammatory events both in synovial tissue and bone, but also to address their potential not only as inducers of inflammation but also as homeostatic regulators. The RA-SCID model is based upon the engraftment of human synovial tissue (from RA patients undergoing surgery) subcutaneously onto the backs of SCID/beige mice where the human transplant tissue remains viable, becomes vascularised and develops a connection with the mouse vasculature. In addition we will also engraft biopsy fragments of femoral bone to address the potential of NK cells to support osteoblast differentiation and activity as well as NK cell effects on osteoclastogenesis in vivo. Migration of cytokine-activated NK cells to synovial tissue and bone in vivo will be assessed by transfer of labelled cells 4 weeks after transplantation and enumeration of migration of the injected cells to the transplanted tissue using imaging techniques, and removal of biopsies with ex vivo enumeration. This proposal will address (for the first time) the potential of NK cells both to contribute to inflammation but also regulate inflammatory events in an in vivo model relevant to human RA disease.</gtr:technicalSummary><gtr:fund><gtr:end>2014-04-01</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2010-04-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>603245</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Imperial College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Life Sciences</gtr:department><gtr:description>The role of NKG2D in Rheumatoid Arthritis</gtr:description><gtr:id>B3B00CC9-40CE-491A-BD5F-64F8E500D539</gtr:id><gtr:impact>We have recently published that blockade of NKG2D can ameliorate disease in an animal model of rheumatoid arthritis. These findings will be confirmed and extended in this collaboration using NKG2D knockout mice (provided by the collaboratior). The aim of this study is to determine if NKG2D expression on NK cells or alternative cell types is responsible for these effects.</gtr:impact><gtr:outcomeId>VABoKRbzR57-1</gtr:outcomeId><gtr:partnerContribution>Our collaborators have provided the knockout strain of mice needed to perform this study as well as intellectual input</gtr:partnerContribution><gtr:piContribution>Intellectual input and expertise in animal models of rheumatoid arthritis</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>MRC Harwell</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>MRC Musculoskeletal Mouse Consortium</gtr:description><gtr:id>71931678-6D89-415F-B1DD-0FE6C79E056B</gtr:id><gtr:impact>Two new knockout mouse have been generated to date. This reduces the budget costs for our research</gtr:impact><gtr:outcomeId>KEXNmXkMDsQ-1</gtr:outcomeId><gtr:partnerContribution>Mice are being generated at MRC Harwell and other centres for distribution to the members of the consortium.</gtr:partnerContribution><gtr:piContribution>The overall aim of this proposal is to establish mouse disease models for human bone and cartilage disorders that include osteoporosis, osteoarthritis, skeletal trauma, chondrocalcinosis, Paget's disease and skeletal dysplasia that will help to elucidate the underlying biological mechanisms and provide in vivo models for pre-clinical studies. The specific objectives are to:

1) Establish mouse models of primary and secondary bone and cartilage disorders.

2) Characterise the phentoypes and pathophysiology, using high-throughput primary and secondary phenotyping platforms, which we have established and include: faxitron quantative digital X-ray analysis of bone mineral content; 3D and micro CT analysis of bone structure and bone mineral density (BMD); in vivo fluorescent imaging; high resolution MRI; biomechanical characterisation of bone in bending and compression of fracture analysis; and histological assessements.

3) Make use of these models to elucidate underlying biological mechanisms, develop biomarkers and facilitate translational research.

Thus, our consortium will have a world-leading impact in the development of novel approaches for the prevention and treatment of the major diseases of bone and cartilage.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Cambridge</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Pathology</gtr:department><gtr:description>Expression of NK ligands by synovial cells</gtr:description><gtr:id>537684C3-D6E2-45B3-8D25-46D2C304FD7F</gtr:id><gtr:impact>We have recently submitted a publication showing that RA synovial cells express ligands for NKG2D. This collaboration will further investigate the particular NKG2D ligands expressed by RA cells - access to clinical samples is provided by us and access to reagents commercially unavailable will be provided by our collaborators. This collaboration will identify NKG2D ligands expressed in RA cells that may play a role in disease progression</gtr:impact><gtr:outcomeId>Tg795Bf1X5q-1</gtr:outcomeId><gtr:partnerContribution>Intellectual input + access to research materials commercially unavailable</gtr:partnerContribution><gtr:piContribution>Intellectual input, access to biological samples</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>120000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>DPhil studentship</gtr:description><gtr:end>2015-10-02</gtr:end><gtr:fundingOrg>University of Oxford</gtr:fundingOrg><gtr:id>98CC4B35-6799-46C1-A110-15A84BB0A4A6</gtr:id><gtr:outcomeId>546479fc5d6079.18802384</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>120000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Kennedy Institute of Rheumatology</gtr:department><gtr:description>DPhil studentship - Kennedy Institute Trust</gtr:description><gtr:end>2017-10-02</gtr:end><gtr:fundingOrg>University of Oxford</gtr:fundingOrg><gtr:id>0E817A89-6E92-474D-9E7B-61AAA28E9E32</gtr:id><gtr:outcomeId>ZCdSgjzuJWq</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-10-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>We have developed an in vivo cell trafficking model allowing the investigation of migration of human cells to human synovial tissue transplants in SCID mice using radiolabelling techniques.</gtr:description><gtr:id>0FCF2809-60E8-4517-B1DC-F07C420C39AE</gtr:id><gtr:impact>This model will allow us to investigate the trafficking of human NK cell subsets to human rheumatoid arthritis synovial tissue within an in vivo setting.</gtr:impact><gtr:outcomeId>d99agE77NN5</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>RA-SCID mouse model</gtr:title><gtr:type>Model of mechanisms or symptoms - mammalian in vivo</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>We have optimised the SKG mouse model of ankylosing spondylitis to investigate the role of NK cells in the destruction and formation of new bone</gtr:description><gtr:id>022B9CF6-2B5D-4E2C-9A5E-0E79B84E8A71</gtr:id><gtr:impact>This model will allow us to detect NK cells at site of bone remodelling and to target them with novel therapeutic strategies arising from the research</gtr:impact><gtr:outcomeId>m7wutnscnCG</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>SKG model of arthritis</gtr:title><gtr:type>Model of mechanisms or symptoms - mammalian in vivo</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>2D3AF2AD-1FE9-4702-8A6A-3EB00EA49B4C</gtr:id><gtr:title>Immune cells and bone: coupling goes both ways.</gtr:title><gtr:parentPublicationTitle>Immunological investigations</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/06117743609e06721ec1079cf4033745"><gtr:id>06117743609e06721ec1079cf4033745</gtr:id><gtr:otherNames>Horwood NJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0882-0139</gtr:issn><gtr:outcomeId>pm_16386_26_24004057</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>93B2AE9E-0D47-4244-83A4-B82EE9B01FAB</gtr:id><gtr:title>Cells of the immune system orchestrate changes in bone cell function.</gtr:title><gtr:parentPublicationTitle>Calcified tissue international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b244257d3e769c0fbf393be2fbe2f15d"><gtr:id>b244257d3e769c0fbf393be2fbe2f15d</gtr:id><gtr:otherNames>Wythe SE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0171-967X</gtr:issn><gtr:outcomeId>pm_16386_26_23912951</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>697CAB6F-C17B-46AE-BAC9-D57C260740BD</gtr:id><gtr:title>The role of Natural Killer cells in the pathogenesis of rheumatoid arthritis: major contributors or essential homeostatic modulators?</gtr:title><gtr:parentPublicationTitle>Immunology letters</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5d308999d2b191c3dd1ed93a8edea33b"><gtr:id>5d308999d2b191c3dd1ed93a8edea33b</gtr:id><gtr:otherNames>Ahern DJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0165-2478</gtr:issn><gtr:outcomeId>pANNbT4erw2</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C676BB4A-ECB7-44A2-843C-D5502DCEEF3C</gtr:id><gtr:title>Low-dose TNF augments fracture healing in normal and osteoporotic bone by up-regulating the innate immune response.</gtr:title><gtr:parentPublicationTitle>EMBO molecular medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ce5be279a44d9f9020df160be8a56257"><gtr:id>ce5be279a44d9f9020df160be8a56257</gtr:id><gtr:otherNames>Chan JK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1757-4676</gtr:issn><gtr:outcomeId>56e034af9c1399.38270123</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BDE3D76C-9418-437E-95BB-5D50CE7B416E</gtr:id><gtr:title>OX40L blockade is therapeutic in arthritis, despite promoting osteoclastogenesis.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2dc28afd332af329245e95f98cb94c01"><gtr:id>2dc28afd332af329245e95f98cb94c01</gtr:id><gtr:otherNames>Gwyer Findlay E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>56e034b00dbc75.87961873</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0900160</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>C6D70A71-8796-47BC-AFE0-CC2286E66A06</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Inflammatory and Immune System</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>